Business Description
ANI Pharmaceuticals Inc
NAICS : 325414
SIC : 2836
ISIN : US00182C1036
Share Class Description:
FRA:BSFA: Ordinary SharesDescription
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.25 | |||||
| Equity-to-Asset | 0.34 | |||||
| Debt-to-Equity | 1.45 | |||||
| Debt-to-EBITDA | 8.91 | |||||
| Interest Coverage | 0.55 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 1.51 | |||||
| Beneish M-Score | -2.67 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.4 | |||||
| 3-Year EBITDA Growth Rate | 35.6 | |||||
| 3-Year Book Growth Rate | 10.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 77.42 | |||||
| Future 3-5Y Total Revenue Growth Rate | 16.55 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 66.11 | |||||
| 9-Day RSI | 59.06 | |||||
| 14-Day RSI | 56.09 | |||||
| 6-1 Month Momentum % | -7.89 | |||||
| 12-1 Month Momentum % | 16.15 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.74 | |||||
| Quick Ratio | 1.97 | |||||
| Cash Ratio | 0.81 | |||||
| Days Inventory | 197.78 | |||||
| Days Sales Outstanding | 115.1 | |||||
| Days Payable | 75.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.3 | |||||
| Shareholder Yield % | -6.98 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 59.79 | |||||
| Operating Margin % | 1.73 | |||||
| Net Margin % | -1.28 | |||||
| FCF Margin % | 13.28 | |||||
| ROE % | -1.54 | |||||
| ROA % | -0.72 | |||||
| ROIC % | 1.32 | |||||
| ROC (Joel Greenblatt) % | 4.5 | |||||
| ROCE % | 1.18 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 10.47 | |||||
| Price-to-Owner-Earnings | 31.14 | |||||
| PS Ratio | 2 | |||||
| PB Ratio | 2.97 | |||||
| Price-to-Free-Cash-Flow | 15.03 | |||||
| Price-to-Operating-Cash-Flow | 11.92 | |||||
| EV-to-EBIT | 172.92 | |||||
| EV-to-EBITDA | 24.23 | |||||
| EV-to-Revenue | 3.06 | |||||
| EV-to-Forward-Revenue | 2.32 | |||||
| EV-to-FCF | 23.08 | |||||
| Price-to-Projected-FCF | 2.4 | |||||
| Price-to-Median-PS-Value | 0.61 | |||||
| Earnings Yield (Greenblatt) % | 0.58 | |||||
| FCF Yield % | 6.12 | |||||
| Forward Rate of Return (Yacktman) % | -22.67 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ANI Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 509.049 | ||
| EPS (TTM) (€) | -0.502 | ||
| Beta | 0.2 | ||
| Volatility % | 32.76 | ||
| 14-Day RSI | 56.09 | ||
| 14-Day ATR (€) | 1.183619 | ||
| 20-Day SMA (€) | 53.9 | ||
| 12-1 Month Momentum % | 16.15 | ||
| 52-Week Range (€) | 44.6 - 64 | ||
| Shares Outstanding (Mil) | 21.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ANI Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ANI Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
ANI Pharmaceuticals Inc Frequently Asked Questions
What is ANI Pharmaceuticals Inc(FRA:BSFA)'s stock price today?
The current price of FRA:BSFA is €55.50. The 52 week high of FRA:BSFA is €64.00 and 52 week low is €44.60.
When is next earnings date of ANI Pharmaceuticals Inc(FRA:BSFA)?
The next earnings date of ANI Pharmaceuticals Inc(FRA:BSFA) is 2025-02-28 Est..
Does ANI Pharmaceuticals Inc(FRA:BSFA) pay dividends? If so, how much?
ANI Pharmaceuticals Inc(FRA:BSFA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers